[Medical treatment of myocardial infarct in the acute phase].
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000700:Analgesics / Q000627:therapeutic use*; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001780:Blood Coagulation Tests; D005081:Exercise Therapy; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005947:Glucose / Q000627:therapeutic use; D006493:Heparin / Q000009:adverse effects; D006801:Humans; D006821:Hyaluronoglucosaminidase / Q000627:therapeutic use; D006854:Hydrocortisone / Q000627:therapeutic use; D007263:Infusions, Parenteral; D007328:Insulin / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000178:diet therapy / Q000188:drug therapy / Q000628:therapy*; D010102:Oxygen Inhalation Therapy; D010423:Pentazocine / Q000627:therapeutic use; D011188:Potassium / Q000627:therapeutic use; D013299:Streptodornase and Streptokinase / Q000627:therapeutic use; D014882:Water-Electrolyte Balance
D000319:Adrenergic beta-Antagonists; D000700:Analgesics; D000925:Anticoagulants; D005343:Fibrinolytic Agents; D007328:Insulin; D006493:Heparin; D013299:Streptodornase and Streptokinase; D006821:Hyaluronoglucosaminidase; D005947:Glucose; D010423:Pentazocine; D011188:Potassium; D006854:Hydrocortisone
Le traitement médical de l'infarctus du myocarde à la phase aiguë